Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

DNA methylation data have become a valuable source of information for biomarker
development, because, unlike static genetic risk estimates, DNA methylation varies …

Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical
decisions in cancer care, they have limited ability to identify the transcriptional programs that …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated
compared with those of healthy controls, but the sources of this extra cfDNA have never …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …